Paul Tudor Jones’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.9M Buy
477,900
+111,200
+30% +$4.78M 0.03% 431
2026
Q1
$13.5M Sell
366,700
-692,500
-65% -$32.8M 0.03% 593
2025
Q4
$53.9M Sell
1,059,200
-911,000
-46% -$46.6M 0.1% 150
2025
Q3
$109M Buy
1,970,200
+1,558,600
+379% +$91.2M 0.19% 68
2025
Q2
$28.4M Buy
411,600
+187,600
+84% +$12.8M 0.06% 244
2025
Q1
$15.6M Buy
224,000
+186,700
+501% +$15.4M 0.05% 290
2024
Q4
$3.21M Buy
37,300
+22,500
+152% +$2.43M 0.01% 937
2024
Q3
$1.76M Buy
14,800
+1,900
+15% +$253K 0.01% 1273
2024
Q2
$1.84M Buy
+12,900
New +$1.71M 0.01% 1129
2024
Q1
Sell
-21,800
Closed -$2.26M 2623
2023
Q4
$2.26M Buy
+21,800
New +$2.16M 0.02% 1035

Other funds holding NVO

Paul Tudor Jones's NVO Position: Q2 2026 in Review

Paul Tudor Jones reduced its Novo Nordisk (NVO) stake by 59% in Q2 2026, selling an estimated $11.1M and leaving 182,382 shares worth $8.74M. The position accounts for 0.01% of the portfolio, ranked #901.

Paul Tudor Jones first reported a position in NVO in Q4 2021 and has held it in 13 quarters since. The position peaked at $22M in Q4 2023. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Paul Tudor Jones held 182,382 shares of Novo Nordisk worth $8.74M as of Q2 2026.
  • Paul Tudor Jones sold 258,235 Novo Nordisk shares in Q2 2026, an estimated $11.1M.
  • Novo Nordisk made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #901 holding.
  • Paul Tudor Jones first reported a position in Novo Nordisk in Q4 2021 and has held it in 13 quarters since.
  • Paul Tudor Jones's Novo Nordisk position peaked at $22M in Q4 2023.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.